Showing results (481-490 of 577) with videos related to
Sort By:
Pageof 58
Clinical Colorectal Cancer|July 26, 2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal CancerRaghav Sundar, Susana Miranda, Daniel Nava Rodrigues, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.Gut|September 5, 2020
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumoursKate Young, Rita T Lawlor, Chanthirika Ragulan, et al.Frontiers in Oncology|October 5, 2020
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial DataKhurum Khan, Reyes Gonzalez-Exposito, David Cunningham, et al.Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.Carcinogenesis|July 7, 2016
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patientsFrancesco Sclafani, Ian Chau, David Cunningham, et al.International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.Scientific Reports|January 25, 2018
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancerFrancesco Sclafani, Ian Chau, David Cunningham, et al.Pageof 58